Valbiotis, Nature Meets Science for Lifelong Good Health

Accueil » About

Our mission

For over a decade, we have been committed to pushing the boundaries of scientific research to offer healthcare professionals and consumers innovative supplements that combine scientific excellence, botanical expertise and the richness of natural ingredients.

Our unique approach brings together state-of-the-art technologies and meticulously selected ingredients to ensure that our products are safe and genuinely beneficial for health.

This approach has allowed us to create a new generation of dietary supplements that are scientifically tested and designed to support health at every stage of life. Be it cardiometabolic health, sleep issues, occasional fatigue, mood management or lack of vitality, our products meet every need with precisely measured active compounds and rigorous scientific validation.

The Science Behind It All

Our Research and Development Team studies the mechanisms of action of the most promising active compounds. Drawing on extensive scientific expertise, rigorous testing, cutting-edge technologies and carefully selected ingredients, we create highly innovative dietary supplements.

Our products are developed primarily through botanical science. Over the years, we have built strong expertise in plant chemistry, biochemistry and bioengineering.

We work closely with La Rochelle University, the CNRS and Clermont Auvergne University to carry out our research and refine our active ingredients. Our teams, specializing in plant chemistry and biotechnology, conduct analyses and optimize each and every formula to ensure we develop the safest and most effective solutions.

Our Proprietary Clinical Studies

After developing the TOTUMs, our patented, proprietary active compounds born out of advanced research in plant biotechnology, we wanted to go one step further by scientifically validating their efficacy. So, we launched a rigorous evaluation program that includes preclinical and clinical studies conducted in partnership with experts and leading hospitals in France and abroad.

The patented active ingredients found in our ValbiotisPRO® range have been tested using strict protocols that adhere to the standards of the pharmaceutical industry. These evaluations provide an in-depth analysis of the active ingredients’ impact on metabolic and cardiovascular markers. The results offer strong evidence of safety and efficacy, reinforcing our commitment to delivering innovative, scientifically tested health solutions.

See our scientific publications

Our history

Launch of ValbiotisPRO® Metabolic Health and ValbiotisPRO® Cardio-Circulation
2025
Our CSR approach receives Lucie 26000 certification
2024
Launch of two Labcom collaborations with Clermont Auvergne University and INRAE, and with La Rochelle University and the CNRS
2024
Our CSR approach receives Lucie 26000 certification
2024
Launch of our first product: ValbiotisPRO® Cholesterol
2024
Positive Phase II/III REVERSE IT results on TOTUM•63 FDA approval of NDI status for a plant extract used in all TOTUM formulas
2023
Positive Phase II clinical results (HEART study) for TOTUM•070 Signing of the United Nations Global Compact and joining of the Global Compact Network France Strategic evolution toward international licensing and distribution agreements and direct commercialization in France
2022
First 3 scientific articles on Lipidrive published in peer-reviewed international journals
2021
ISO 9001 certification obtained for all operations
2021
Three new active substances added to the pipeline: TOTUM•070, TOTUM•854 and TOTUM•448
2020
Listing on the Euronext Growth stock market TOTUM•63: Presentation of Phase I/II clinical results at the 77th Scientific Sessions of the American Diabetes Association in San Diego (California, USA)
2017
Discovery of the active substance TOTUM•63, first study and patent filing
2015
The company is founded in La Rochelle.
2014

Our governance

After completing a thesis on nutrition in the field of cardiovascular and metabolic diseases at the Laboratory of Applied and Fundamental Bioenergetics (U1055 INSERM) at Joseph Fourier University (Grenoble, France) under the supervision of Professor Xavier Leverve, Sébastien worked at a spin-off of the Free University of Brussels in Belgium on a drug candidate in the area of enteral and parenteral nutrition. In 2007, he joined the Lescuyer Laboratory, where he was rapidly entrusted with management of the Research & Development Department. In this position, he notably oversaw the entire application process for one of the only health claims ever to obtain a positive response from the EFSA for reducing a risk factor for cardiovascular diseases. Sébastien chaired the Biopôle Santé – Réseau Expert, Territoire d’Innovation, Service de Valorisation en Santé (regional expert network for innovation and optimization in the health sector) for the Poitou-Charentes region and later for Nouvelle-Aquitaine for over five years until March 2017. He was also granted the French higher degree authorizing the supervision of research (HDR – Habilitation à Diriger des Recherches) from Blaise Pascal University (which later became the University of Clermont Auvergne, Clermont-Ferrand), allowing him to officially supervise PhD students. Sébastien is an active member of the French Nutrition Society and the American Diabetes Association. He is also a member of the Strategic Committee of La Rochelle Technopole and President of the La Rochelle University Foundation. Sébastien has written over 35 international scientific articles and papers, and has developed more than five patent families.

With over 15 years of research experience, Pascal has exceptional expertise in metabolic diseases. Pascal was a Lecturer at the University of Clermont Auvergne between 2008 and 2018, and has headed the institution’s technical functional assessment platform since 2010. He has also launched several international scientific partnerships with Vanderbilt University (Nashville, USA), the Maine Medical Center Research Institute (Portland, USA) and the University of Texas (Houston, USA) with regard to research projects on the pathophysiology of type 2 diabetes. In 2005, Pascal graduated with a PhD in Biological and Biochemical Health Sciences from Montpellier University and was also granted the French higher degree authorizing the supervision of research (HDR – Habilitation à Diriger des Recherches) in 2016. Pascal has been heavily involved in Valbiotis since it was founded in 2014. As a member of the Scientific Committee, Pascal was in charge of collaborative projects involving the University of Clermont Auvergne and Valbiotis. In 2017, he was appointed Chief Scientific Officer (CSO) at Valbiotis and took over management of the Discovery and Preclinical and Translational Research Department. As such, Pascal is also at the helm of our two R&D centers in La Rochelle and Riom. Furthermore, he is the co-inventor of a number of key technologies used for the development of Valbiotis.

With solid experience in the pharmaceutical sector, Sébastien Poncet has contributed to the growth of major companies, notably in Consumer Healthcare at Mayoly Spindler, Menarini ans Omega Pharma, where he strengthened brand competitiveness and developed effective sales strategies. His expertise in managing commercial networks and negotiating strategic agreements has enabled him to successfully steer the development of business units and secure companies' positions in a constantly evolving market. Today, he puts his know-how at the service of the Valbiotis France Business Unit, where he optimizes sales performance, deploys innovative strategies and supports teams in achieving ambitious objectives, thus consolidating the company's growth and competitiveness.

After starting his career in an audit firm at PwC, Stanislas worked at Urgo laboratories in various positions in Management Control and Financial Control for 4 years then at Sanofi-pasteur-MSD for 10 years in the functions of controller. management, transformation finance project manager and finance direction, both nationally and internationally. He then embarked on an entrepreneurial experience as a part-time DAF for 5 years at Acting Executive, (while assuming Operational Management), during which he notably supported start-ups and SMEs on missions structuring the Finance function but also building a business plan or seeking financing. He then served as CFO at Mablink Biosciences, where he supported the company's various stages of transformation, including the M&A transaction at Lilly & Company.

Laurent has a PhD in Physics and Chemistry, with a specialization in nanomaterials, from the Pierre and Marie Curie University and the CEA (French Commission for Atomic Energy), and a Master of Advanced Studies in Condensed Matter Physics from UPVI-ESPCI (Paris). He has acquired extensive experience in the science and techniques associated with nanomedicine, a field in which he has worked for over a decade. His research is at the forefront of chemistry, biology and physics, and has enabled him to design a certain number of practical applications in nanomedicine, such as the NanoXray technology, which could herald the start of a new era in cancer treatment. Before founding Nanobiotix in 2003, for several years, Laurent worked as a consultant in the development of nanotechnology applications for groups such as Sanofi (pharma), Guerbet (medical imaging) and Rhodia (chemistry), as well as for biotech start-ups. The author of 35 international scientific publications and papers, Laurent has filed many patents and topped off his career with a post-doctorate at the Institute for Lasers, Photonics and Biophotonics of SUNY (State University of New York), Buffalo, in the United States.

Jean has over 30 years’ experience in various international executive positions and cutting-edge expertise in the pharmaceutical and nutrition sectors, their environments and their challenges. The Scientific Director of NOVARTIS Pharma SAS, and then Special Scientific Adviser to the CEO and a member of the Executive Committee, Jean was also Chief Medical Officer and a member of the Executive Committee of Nestlé Health Science in Vevey, Switzerland, for two years, contributing to the growth of the personalized medicine and health nutrition business segments. For close to 20 years, Jean also held various executive and R&D positions at SANOFI, including that of Vice-President and Head of Market Access, Vice-President and Head of Global Regulatory Affairs, and Vice-President and Deputy Head of Global Medical Affairs. Jean is also Vice-President of ARIIS (alliance for research and innovation in health industries) and Chairman of the working group on the attractiveness of France for clinical research headed by Leem, an association of French pharmaceutical companies. Before joining the pharmaceutical industry, Dr. Zetlaoui was a hospital practitioner at the Bicêtre University Hospital (CHU). Jean has a PhD in Medicine and is specialized in anesthesia and resuscitation. He also completed an Executive MBA in Finance and International Business at the ESSEC Business School (1991).

A graduate of ICN Business School in Nancy, with a post-graduate degree in accounting (DECS), and a member of the French Society of Financial Analysts (SFAF), Agnès began her career in 1986 at the Banque de Vizille, specialized in mid-cap transactions, which merged in 2011 with other entities of the Crédit Mutuel Alliance Fédérale group to create CM-CIC INVESTISSEMENT. From 1990 to 1997, she served as Financial Director and Board Member of the SHB hotel group in Lyon, which went on to merge with ACCOR. In 1997, she joined AVENIR TELECOM, a distributor specialized in mobile telephony, for whom she led the initial public offering on Eurolist C in November 1998. For 17 years, as the Administrative and Financial Director of the group (1,800 employees and €290 million in revenue in 2015), she managed a number of mergers and acquisitions and also oversaw investor relations. In 2015, she was appointed Financial Director of the transport and logistics group TRANSALLIANCE (3,000 employees and €600 million in revenue), which operates in seven European countries. From June 2016 to February 2018, she was the Administrative and Financial Director at IDEOL, an innovative company created in 2010 in La Ciotat (46 employees, €4 million in revenue) and a leader in floating offshore wind power.